Peptide therapeutics continue to expands its application by broaden molecular diversity and by engineering enhanced pharmaceutical properties. Research continues to expand the potential range of peptide-based pharmaceuticals to focus on treatment targets. However, large number of peptide targets shown in its early-stage of clinical trials or in preclinical models of disease, such as a melanocortin 4 receptor (MC4R) agonist, may reduce the body weight of patients with genetic obesity syndromes.
Furthermore, increasing development are in progress to extend the half-life period of peptide drugs; to improve the oral bioavailability of peptide therapeutics and to enhance the Central Nervous System (CNS) availability of peptide drugs through nanoparticle delivery in the indications such as Alzheimer’s disease and stroke.
Market Dynamics
Market players are engaged in developing novel and innovative peptide therapeutics drugs in order to offer tailored solution to target patient by increasing biocompatibility and potent therapeutic effects. Increasing prevalence of cancer and diabetes mellitus is projected to drive growth of the peptide therapeutics market over the forecast period. Also, clinical development in the field of peptide reflects it as an effective tool for molecular pharmacology.
Key features of the study:
- This report provides in-depth analysis of peptide therapeutics in medical sector and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global peptide therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Co. Ltd., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Encycle Therapeutics, Inc., CirclePharma, Inc., Pfizer Inc., Novartis AG, PeptiDream Inc., Amgen Inc., among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
- The global peptide therapeutics market report caters to various stakeholders in this industry including investors, suppliers, peptide therapeutics based product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the peptide therapeutics market.
Detailed Segmentation:
- Global Peptide Therapeutics Market, By Type:
- Branded Peptide
- Generic Peptide
- Global Peptide Therapeutics Market, By Application:
- Cancer
- Cardiovascular Disease
- Metabolic Disease
- Respiratory Disease
- Infectious Disease
- Others
- Global Peptide Therapeutics Market, By Route of Administration:
- Oral Administration
- Parenteral Administration
- Others
- Global Peptide Therapeutics Market, By Geography:
- North America
- By Country:
- By Type:
- Branded Peptide
- Generic Peptide
- By Application
- Cancer
- Cardiovascular Disease
- Metabolic Disease
- Respiratory Disease
- Infectious Disease
- Others
- By Route of Administration:
- Oral Administration
- Parenteral Administration
- Others
- Europe
- By Country:
- Germany
- France
- Italy
- UK
- Spain
- Russia
- Rest of Europe
- By Type:
- Branded Peptide
- Generic Peptide
- By Application
- Cancer
- Cardiovascular Disease
- Metabolic Disease
- Respiratory Disease
- Infectious Disease
- Others
- By Route of Administration:
- Oral Administration
- Parenteral Administration
- Others
- Asia Pacific
- By Country:
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia Pacific
- By Type:
- Branded Peptide
- Generic Peptide
- By Application
- Cancer
- Cardiovascular Disease
- Metabolic Disease
- Respiratory Disease
- Infectious Disease
- Others
- By Route of Administration:
- Oral Administration
- Parenteral Administration
- Others
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Type:
- Branded Peptide
- Generic Peptide
- By Application
- Cancer
- Cardiovascular Disease
- Metabolic Disease
- Respiratory Disease
- Infectious Disease
- Others
- By Route of Administration:
- Oral Administration
- Parenteral Administration
- Others
- Latin America
- By Country:
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- By Type:
- Branded Peptide
- Generic Peptide
- By Application
- Cancer
- Cardiovascular Disease
- Metabolic Disease
- Respiratory Disease
- Infectious Disease
- Others
- By Route of Administration:
- Oral Administration
- Parenteral Administration
- Others
- Africa
- By Country:
- South Africa
- Central Africa
- North Africa
- By Type:
- Branded Peptide
- Generic Peptide
- By Application
- Cancer
- Cardiovascular Disease
- Metabolic Disease
- Respiratory Disease
- Infectious Disease
- Others
- By Route of Administration:
- Oral Administration
- Parenteral Administration
- Others
- Company Profiles
- Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments
- Strategies
- Takeda Pharmaceuticals Co. Ltd.
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi S.A.
- Encycle Therapeutics, Inc.
- CirclePharma, Inc.
- Pfizer Inc.
- Novartis AG
- PeptiDream Inc.
- Amgen Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Content - Peptide Therapeutics Market
